Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study.

Autor: Vasylyev, Marta¹ (AUTHOR), Wit, Ferdinand W N M² (AUTHOR), Jordans, Carlijn C E¹ (AUTHOR), Soetekouw, Robin³ (AUTHOR), Lelyveld, Steven F L van³ (AUTHOR), Kootstra, Gert-Jan⁴ (AUTHOR), Delsing, Corine E⁴ (AUTHOR), Ammerlaan, Heidi S M⁵ (AUTHOR), Kasteren, Marjo E E van⁶ (AUTHOR), Brouwer, Annemarie E⁶ (AUTHOR), Leyten, Eliane M S⁷ (AUTHOR), Claassen, Mark A A⁸ (AUTHOR), Hassing, Robert-Jan⁸ (AUTHOR), Hollander, Jan G den⁹ (AUTHOR), van den Berge, Marcel¹⁰ (AUTHOR), Roukens, Anna H E¹¹ (AUTHOR), Bierman, Wouter F W¹² (AUTHOR), Groeneveld, Paul H P¹³ (AUTHOR), Lowe, Selwyn H¹⁴ (AUTHOR), Welzen, Berend J van¹⁵ (AUTHOR)

Publikováno v: Open Forum Infectious Diseases. Apr2024, Vol. 11 Issue 4, p1-10. 10p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The epidemiology of human papillomavirus infection in HIV-positive and HIV-negative high-risk women in Kigali, Rwanda

Autor: Veldhuijzen Nienke J, Braunstein Sarah L, Vyankandondera Joseph, Ingabire Chantal, Ntirushwa Justin, Kestelyn Evelyne, Tuijn Coosje, Wit Ferdinand W, Umutoni Aline, Uwineza Mireille, Crucitti Tania, van de Wijgert Janneke HHM

Publikováno v: BMC Infectious Diseases, Vol 11, Iss 1, p 333 (2011)

Abstract Background The prevalence, incidence and persistence of human papillomavirus (HPV) types in sub-Saharan Africa are not well established. The objectives of the current study are to describe (predictors of) the epidemiology of HPV among high-r

Externí odkaz: https://doaj.org/article/2cc1a00abcca4ef39b4106fca994ab17

Long-term evolution of comorbidities and their disease burden in individuals with and without HIV as they age: analysis of the prospective AGEhIV cohort study

Autor: Reiss, P., Wit, F.W.N.M., van der Valk, M., Schouten, J., Kooij, K.W., van Zoest, R.A., Verheij, E., Verboeket, S.O., Elsenga, B.C., Prins, M., Schim van der Loeff, M.F., del Grande, L., Olthof, V., Agard, I., Zaheri, S., Hillebregt, M.M.J., Ruijs, Y.M.C., Benschop, D.P., el Berkaoui, A., Kootstra, N.A., Harskamp-Holwerda, A.M., Maurer, I., Mangas Ruiz, M.M., Girigorie, A.F., Boeser-Nunnink, B., Zikkenheiner, W., Nolst Trenité, S., Geerlings, S.E., Goorhuis, A., Hovius, J.W.R., Nellen, F.J.B., van der Poll, T., Prins, J.M., Wiersinga, W.J., van Vugt, M., de Bree, G., van Eden, J., van Hes, A.M.H., Pijnappel, F.J.J., Weijsenfeld, A., Smalhout, S., van Duinen, M., Hazenberg, A., Postema, P.G., Bisschop, P.H.L.T., Serlie, M.J.M., Lips, P., Dekker, E., Dekker, N., Willemsen, J.M.R., Vogt, L., Verheij, Eveline ^{*, *}, Boyd, Anders ^*, Wit, Ferdinand W, Verboeket, Sebastiaan O, Verburgh, Myrthe L, van der Valk, Marc, Schim van der Loeff, Maarten F, Reiss, Peter

Publikováno v: In The Lancet HIV March 2023 10(3):e164-e174

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.